Page 69 - Read Online

Feusier et al. J Transl Genet Genom 2021;5:189-99 https://dx.doi.org/10.20517/jtgg.2021.05 Page 199

37. Acunzo M, Romano G, Wernicke D, et al. Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. Blood
2014;124:259-62. DOI PubMed PMC
38. Redondo-Muñoz J, García-Pardo A, Teixidó J. Molecular players in hematologic tumor cell trafficking. Front Immunol 2019;10:156.
DOI PubMed PMC
39. Kriston C, Plander M, Márk Á, et al. In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic
lymphocytic leukemia (CLL) cells on the microenvironment. Ann Hematol 2018;97:2145-52. DOI PubMed
40. Hacken E, Burger JA. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
Pharmacol Ther 2014;144:338-48. DOI PubMed
41. Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Blood 2016;128:1609-13. DOI PubMed PMC
42. Martini V, Gattazzo C, Frezzato F, et al. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4
signalling pathway in chronic lymphocytic leukaemia cells. Br J Haematol 2017;178:81-93. DOI PubMed
43. Kashyap MK, Kumar D, Jones H, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell
death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 2016;7:2809-22.
DOI PubMed PMC
44. Secchiero P, Voltan R, Rimondi E, et al. The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.
Oncotarget 2017;8:59235-45. DOI PubMed PMC
45. Shaim H, Estrov Z, Harris D, et al. The CXCR4-STAT3-IL-10 pathway controls the immunoregulatory function of chronic
lymphocytic leukemia and is modulated by lenalidomide. Front Immunol 2017;8:1773. DOI PubMed PMC
46. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 2015;372:1430-
40. DOI PubMed
47. Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. In: Pomper MG, Fisher PB, editors. Emerging
applications of molecular imaging to oncology. Amsterdam: Elsevier; 2014. p. 31-82.
48. Scala S. Molecular pathways: targeting the CXCR4-CXCL12 axis--untapped potential in the tumor microenvironment. Clin Cancer
Res 2015;21:4278-85. DOI PubMed
49. Lee Y, Yoon KA, Joo J, et al. Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide
association study. Carcinogenesis 2013;34:307-13. DOI PubMed
50. Enjuanes A, Benavente Y, Bosch F, et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of
chronic lymphocytic leukemia. Cancer Res 2008;68:10178-86. DOI PubMed
51. Crowther-Swanepoel D, Qureshi M, Dyer MJ, et al. Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. Blood
2009;114:4843-6. DOI PubMed
52. Milanesi S, Locati M, Borroni EM. Aberrant CXCR4 signaling at crossroad of WHIM syndrome and Waldenstrom's
macroglobulinemia. Int J Mol Sci 2020;21:5696. DOI PubMed PMC
53. Tiao G, Improgo MR, Tausch E, et al. Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. Blood
2017;130:2443-4. DOI PubMed PMC